219 related articles for article (PubMed ID: 30314618)
21. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
22. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
[TBL] [Abstract][Full Text] [Related]
24. Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine.
Hoogendoorn M; Corro Ramos I; Baldwin M; Gonzalez-Rojas Guix N; Rutten-van Mölken MPMH
Value Health; 2019 Mar; 22(3):313-321. PubMed ID: 30832969
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of rituximab in follicular lymphoma.
Johnston KM; Bolbocean C; Connors J; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
[TBL] [Abstract][Full Text] [Related]
26. Economic burden of follicular non-Hodgkin's lymphoma.
Foster T; Miller JD; Boye ME; Russell MW
Pharmacoeconomics; 2009; 27(8):657-79. PubMed ID: 19712009
[TBL] [Abstract][Full Text] [Related]
27. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
[TBL] [Abstract][Full Text] [Related]
28. [Rituximab cost analysis for maintenance treatment of patients with follicular lymphoma].
Grupo de Farmacoeconomía del Linfoma Folicular
Farm Hosp; 2008; 32(1):25-34. PubMed ID: 18426699
[TBL] [Abstract][Full Text] [Related]
29. Economic Decision Model Suggests Total Shoulder Arthroplasty is Superior to Hemiarthroplasty in Young Patients with End-stage Shoulder Arthritis.
Bhat SB; Lazarus M; Getz C; Williams GR; Namdari S
Clin Orthop Relat Res; 2016 Nov; 474(11):2482-2492. PubMed ID: 27457626
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
[TBL] [Abstract][Full Text] [Related]
32. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
Prasad S; Arellano J; Steer C; Libretto SE
Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
34. Lifetime Costs for Treated Follicular Lymphoma Patients in the US.
Eichten C; Ma Q; Delea TE; Hagiwara M; Ramos R; Iorga ŞR; Zhang J; Maziarz RT
Pharmacoeconomics; 2021 Oct; 39(10):1163-1183. PubMed ID: 34273085
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
[TBL] [Abstract][Full Text] [Related]
36. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
39. Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann-Pick Type C disease among intellectually disabled using discrete event simulation.
van Karnebeek CD; Mohammadi T; Tsao N; Sinclair G; Sirrs S; Stockler S; Marra C
Mol Genet Metab; 2015 Feb; 114(2):226-32. PubMed ID: 25095726
[TBL] [Abstract][Full Text] [Related]
40. Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.
Danese MD; Reyes CM; Gleeson ML; Halperin M; Skettino SL; Mikhael J
Med Care; 2016 Apr; 54(4):343-9. PubMed ID: 26759977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
